NY-ALVAREZ-&-MARSAL
11.1.2024 16:01:30 CET | Business Wire | Press release
Leading global professional services firm Alvarez & Marsal (A&M) has announced the promotion of 69 professionals, across Europe and Middle East, India, Latin America, North America, North Asia and Southeast Asia & Australia to the position of Managing Director.
Tony Alvarez II and Bryan Marsal, A&M’s Co-Founders, stated, “Congratulations to all our newly promoted Managing Directors. Their contributions to our core values of integrity, quality, objectivity, fun, personal reward and inclusive diversity are what make A&M unique. Their commitment to help clients maximize value and drive change amidst ongoing macro-economic challenges builds upon our legacy of operational excellence while advancing our results-oriented mission. They, alongside all A&M professionals, are our greatest strength.”
2024 MANAGING DIRECTOR PROMOTIONS
Europe and Middle East
- Cristiano Battelli, Private Equity Performance Improvement -- Milan
- Paul Culham, Global Transaction Advisory Group -- London
- Louis Darrieus, Global Transaction Advisory Group -- Paris
- Steve Green, Debt Advisory -- London
- Josefine Haensel, Corporate Transformation Services -- Hamburg
- Samih Hajar, Global Transaction Advisory Group -- Paris
- Cheng He, Global Transaction Advisory Group -- London
- Michal Kapela, Global Transaction Advisory Group -- Zurich
- Zeeshan Mansoor, Financial Services Industry -- Amsterdam
- Michael Nizet, Financial & Operational Restructuring -- Amsterdam
- Robert Park, Corporate Transformation Services -- London
- Tom Paterson, Debt Advisory -- London
- Adam Paxton, Insolvency -- London
- Felix Schweigger, Private Equity Performance Improvement -- Munich
- Steve Smith, Tax -- London
- Sebastien Trochet, Digital & Technology Services -- Paris
- Yann Varin, Private Equity Performance Improvement -- Paris
- Nick Walton, Tax -- Manchester
India
- Ashish Doshi, Global Transaction Advisory Group -- Mumbai
- Ram Panda, Business Transformation Services -- Mumbai
Latin America
- Guilherme Almeida, Corporate Transformation -- São Paulo
- Luiz Gronau, Infrastructure & Capital Projects (A&M INFRA) -- São Paulo
- Eduardo Magalhaes, Global Disputes and Investigations -- São Paulo
North America
- Richard Behrens, North American Commercial Restructuring -- Los Angeles
- Brett Bergamo, Energy -- Houston
- Amy Best, Global Disputes and Investigations -- Denver
- Matthew Box, Healthcare -- Washington, D.C.
- Aaron Busse, Corporate Performance Improvement -- Atlanta
- Meghan Cardell, Global Disputes and Investigations -- Washington, D.C.
- Evan Colwell, Global Transaction Advisory Group -- Nashville
- Steve Coverick, North American Commercial Restructuring -- Dallas
- Jorge de Los Reyes, Infrastructure & Capital Projects (A&M INFRA) -- Washington, D.C.
- Beata De Zagon, Global Transaction Advisory Group -- Dallas
- Alex Duff, Private Equity Performance Improvement -- New York
- Ryan Duffy, Global Transaction Advisory Group -- Chicago
- Kyle Foust, Tax -- Chicago
- Max Fulton, Private Equity Performance Improvement -- Denver
- Jen Fults, Tax -- New York
- Jeffrey Gerarde, Tax -- Washington, D.C.
- John Hanson, North American Commercial Restructuring -- Dallas
- Sam Jones, Global Transaction Advisory Group -- Chicago
- Andrew Khoo, North American Commercial Restructuring -- New York
- David Knight, Private Equity Performance Improvement -- Houston
- Daniel LaMantia, Private Equity Performance Improvement -- Dallas
- Erin Leveton, Public Sector Services -- Washington, D.C.
- Allen Mahr, North American Commercial Restructuring -- New York
- Matthew Merhan, Corporate Performance Improvement -- Houston
- Derek Myers, Tax -- Atlanta
- Rich Niemerg, North American Commercial Restructuring -- Chicago
- Alan Pender, Energy -- Dallas
- Rob Reid, Infrastructure & Capital Projects (A&M INFRA) -- Atlanta
- Jeffrey Richman, Corporate Finance -- New York
- Brian Rudelson, Tax -- Houston
- Joan Russo, Healthcare -- Miami
- Paul Saftig, Global Transaction Advisory Group -- Chicago
- John Sawyer, Valuation -- Seattle
- Daniel Schmeltz, Corporate Performance Improvement -- Houston
- Jigar Shah, Corporate Performance Improvement -- Los Angeles
- Michael Shanahan, Global Disputes and Investigations -- Philadelphia
- Jeff Swerdlow, Tax -- Denver
- Andrew Thung, Healthcare -- New York
- Jeremy Tilsner, Global Disputes and Investigations -- New York
- Andrey Ulyanenko, Tax -- Miami
- Aaron Umberger, Public Sector Services -- Washington, D.C.
- Mariya Verbitski, Global Transaction Advisory Group -- San Francisco
North Asia
- Dee Chung, Restructuring & Turnaround -- Seoul
- Carmen Yeung, Restructuring & Turnaround -- Hong Kong SAR
Southeast Asia & Australia
- John Sanger, Performance Improvement -- Perth
- Kaustav Sen, Performance Improvement -- Singapore
About Alvarez & Marsal
Companies, investors and government entities around the world turn to Alvarez & Marsal (A&M) for leadership, action and results. Privately held since its founding in 1983, A&M is a leading global professional services firm that provides advisory, business performance improvement and turnaround management services. When conventional approaches are not enough to create transformation and drive change, clients seek our deep expertise and ability to deliver practical solutions to their unique problems.
With over 8,500 people across six continents, we deliver tangible results for corporates, boards, private equity firms, law firms and government agencies facing complex challenges. Our senior leaders, and their teams, leverage A&M’s restructuring heritage to help companies act decisively, catapult growth and accelerate results. We are experienced operators, world-class consultants, former regulators and industry authorities with a shared commitment to telling clients what’s really needed for turning change into a strategic business asset, managing risk and unlocking value at every stage of growth.
To learn more, visit: AlvarezandMarsal.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240109034313/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
